Year All2024202320222021202020192018201720162015201420132012201120102007 01.07.22 Syndax Announces Presentation at 40th Annual J.P. Morgan Healthcare Conference WALTHAM, Mass. , Jan. 7, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Read More 12.22.21 Syndax Announces Orphan Drug Designation Granted to SNDX-5613 by European Commission for the Treatment of Acute Myeloid Leukemia WALTHAM, Mass. , Dec. 22, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the European Commission has granted Orphan Drug Read More 12.20.21 Syndax Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares WALTHAM, Mass. , Dec. 20, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the closing of its previously announced underwritten public Read More 12.15.21 Syndax Announces Pricing of $75.3 Million Public Offering WALTHAM, Mass. , Dec. 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the pricing of an underwritten public offering of 3,157,144 Read More 12.15.21 Syndax Announces Proposed Public Offering of Common Stock WALTHAM, Mass. , Dec. 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it plans to offer and sell, subject to market and Read More 12.13.21 Syndax Pharmaceuticals Announces Additional Positive Data Demonstrating Continued Robust Clinical Activity with Durable Responses in Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 - 55% overall response rate and 24% CR/CRh rate in relapsed/refractory acute leukemia patients with NPM1 or MLLr mutations; no discontinuations due to treatment-related adverse events - - CR/CRh rates of 23% and 24% in mNPM1 and MLLr patients, respectively - - CR/CRh responses were durable; median Read More 12.11.21 Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease - 68% overall response rate and broad multiorgan clinical benefit observed in highly refractory patients treated at doses being assessed in ongoing AGAVE-201 pivotal study - - Axatilimab well-tolerated at all doses and schedules - WALTHAM, Mass. , Dec. Read More 12.09.21 Syndax Pharmaceuticals Announces Closing of Global Collaboration and License Agreement for Axatilimab WALTHAM, Mass. , Dec. 9, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) announced today that the Hart-Scott-Rodino (HSR) antitrust waiting period had expired and that the parties closed the exclusive worldwide collaboration and license agreement between Syndax and Incyte to Read More 11.15.21 Syndax Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Business Update - Initiated pivotal Phase 2 portion of SNDX-5613 AUGMENT-101 trial in patients with NPM1 and MLLr acute leukemias - - Entered global collaboration with Incyte to develop and commercialize axatilimab for cGVHD and other fibrotic diseases - - Updated data from SNDX-5613 and axatilimab clinical Read More 11.08.21 Syndax to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 15, 2021 WALTHAM, Mass. , Nov. 8, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its third quarter 2021 financial Read More 11.04.21 Syndax Pharmaceuticals to Present Updated Data from SNDX-5613 and Axatilimab Clinical Programs During Oral Sessions at 63rd ASH Annual Meeting - Robust clinical activity with durable responses and no discontinuations due to treatment-related adverse events observed in Phase 1 portion of AUGMENT-101 trial of SNDX-5613 in relapsed or refractory patients with genetically-defined acute leukemias - - Phase 2 results highlight broad efficacy Read More 09.27.21 Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases - Syndax to receive $ 152 million in cash ($117 million upfront plus a $35 million equity investment, with potential for $450 million in additional milestone payments; 50:50 profit share in the U.S. and double-digit royalties on ex-U.S. sales - - The two companies expect to expand development of Read More
01.07.22 Syndax Announces Presentation at 40th Annual J.P. Morgan Healthcare Conference WALTHAM, Mass. , Jan. 7, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Read More
12.22.21 Syndax Announces Orphan Drug Designation Granted to SNDX-5613 by European Commission for the Treatment of Acute Myeloid Leukemia WALTHAM, Mass. , Dec. 22, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the European Commission has granted Orphan Drug Read More
12.20.21 Syndax Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares WALTHAM, Mass. , Dec. 20, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the closing of its previously announced underwritten public Read More
12.15.21 Syndax Announces Pricing of $75.3 Million Public Offering WALTHAM, Mass. , Dec. 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the pricing of an underwritten public offering of 3,157,144 Read More
12.15.21 Syndax Announces Proposed Public Offering of Common Stock WALTHAM, Mass. , Dec. 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it plans to offer and sell, subject to market and Read More
12.13.21 Syndax Pharmaceuticals Announces Additional Positive Data Demonstrating Continued Robust Clinical Activity with Durable Responses in Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 - 55% overall response rate and 24% CR/CRh rate in relapsed/refractory acute leukemia patients with NPM1 or MLLr mutations; no discontinuations due to treatment-related adverse events - - CR/CRh rates of 23% and 24% in mNPM1 and MLLr patients, respectively - - CR/CRh responses were durable; median Read More
12.11.21 Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease - 68% overall response rate and broad multiorgan clinical benefit observed in highly refractory patients treated at doses being assessed in ongoing AGAVE-201 pivotal study - - Axatilimab well-tolerated at all doses and schedules - WALTHAM, Mass. , Dec. Read More
12.09.21 Syndax Pharmaceuticals Announces Closing of Global Collaboration and License Agreement for Axatilimab WALTHAM, Mass. , Dec. 9, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) announced today that the Hart-Scott-Rodino (HSR) antitrust waiting period had expired and that the parties closed the exclusive worldwide collaboration and license agreement between Syndax and Incyte to Read More
11.15.21 Syndax Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Business Update - Initiated pivotal Phase 2 portion of SNDX-5613 AUGMENT-101 trial in patients with NPM1 and MLLr acute leukemias - - Entered global collaboration with Incyte to develop and commercialize axatilimab for cGVHD and other fibrotic diseases - - Updated data from SNDX-5613 and axatilimab clinical Read More
11.08.21 Syndax to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 15, 2021 WALTHAM, Mass. , Nov. 8, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its third quarter 2021 financial Read More
11.04.21 Syndax Pharmaceuticals to Present Updated Data from SNDX-5613 and Axatilimab Clinical Programs During Oral Sessions at 63rd ASH Annual Meeting - Robust clinical activity with durable responses and no discontinuations due to treatment-related adverse events observed in Phase 1 portion of AUGMENT-101 trial of SNDX-5613 in relapsed or refractory patients with genetically-defined acute leukemias - - Phase 2 results highlight broad efficacy Read More
09.27.21 Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases - Syndax to receive $ 152 million in cash ($117 million upfront plus a $35 million equity investment, with potential for $450 million in additional milestone payments; 50:50 profit share in the U.S. and double-digit royalties on ex-U.S. sales - - The two companies expect to expand development of Read More